Minalrestat  (Synonyms: ARI-509; WAY-ARI 509)

Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes^[1].

Minalrestat (100 μM) 减少原代培养的大鼠系细胞内山梨糖醇含量，而不影响的细胞内葡萄糖含量^[3]。
Minalrestat (100 μM, 48 h) 在原代培养的大鼠系膜细胞中引起 PKC-α 和 -β2 的积累^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Minalrestat (口服灌胃，10 mg/kg/天，持续 30 天) 可恢复糖尿病大鼠中降低的微血管反应性^[1]。
Minalrestat (口服灌胃，10 mg/kg) 可恢复糖尿病大鼠毛细血管后微静脉中减少的白细胞粘附和迁移白细胞数量^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

449.20

C₁₉H₁₁BrF₂N₂O₄

129688-50-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Akamine EH, et al. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42.  [Content Brief]

  [2]. Cruz JW, et al. Minalrestat and leukocyte migration in diabetes mellitus. Diabetes Metab Res Rev. 2003 May-Jun;19(3):223-31.  [Content Brief]

  [3]. Kapor-Drezgic J, et al. Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol. 1999 Jun;10(6):1193-203.  [Content Brief]